Comparing plasma p-tau217 and plasma p-tau217/Aβ_42 with CSF biomarkers for assessing Alzheimer’s disease pathology

Warmenhoven, Noëlle, Binette, Alexa Pichet, Collij, Lyduine E., Janelidze, Shorena, Mattsson-Carlgren, Niklas, Tideman, Pontus, Smith, Ruben, Strandberg, Olof, Ashton, Nicholas J., Zetterberg, Henrik, Stomrud, Erik, Salvadó, Gemma, Hansson, Oskar, Palmqvist, Sebastian, Alzheimer’s Disease Neuroimaging Initiative
Nature Aging · Springer Nature · 2026-11-18 · DOI: 10.1038/s43587-026-01259-z

Abstract

Plasma biomarkers for Alzheimer’s disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio (p-tau217/Aβ_42) with regulatory-authorized cerebrospinal fluid (CSF) biomarkers (Aβ_42/Aβ_40 and p-tau181/Aβ_42) for identifying AD pathology (Aβ-PET visual read) across a memory clinic ( n = 129), a primary care ( n = 220) and a research cohort ( n = 165). Regulatory-authorized cutoffs were used for the plasma and CSF biomarkers. Plasma biomarkers identified Aβ pathology with areas under the curve between 0.90 and 0.96. Using one cutoff, plasma p-tau217 (83–91%) and p-tau217/Aβ_42 (83–92%) had comparable accuracies to CSF (88–90%) across all cohorts (all P ≥ 0.05). With a two-cutoff approach, plasma p-tau217 (90–97%) remained comparable to CSF (91%) in the clinical cohorts (all P _adj ≥ 0.12). Results with cohort-derived cutoffs are also provided. In conclusion, regulatory-authorized plasma p-tau217 and p-tau217/Aβ_42 demonstrated performance comparable to regulatory-authorized CSF tests for detecting Aβ pathology in symptomatic individuals. Blood tests for Alzheimer’s disease, including regulatory authorized p-tau217 and p-tau217/AB_42, are accessible and cost-effective diagnostic tools. This study shows that they perform similarly to authorized cerebrospinal fluid tests in detecting Alzheimer’s disease pathology in patients.

Read at publisher →

Similar articles